Clinical Trial Update: A Study to Evaluate Safety and Efficacy of AMZ002 Treatment, Compared With Vigabatrin in Participants With Infantile Spasms [Phase 3]

View source ↗

Summary

Phase 3 trial comparing AMZ002 to vigabatrin for infantile spasms was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infantile Spasms

Drugs mentioned

• AMZ002 (AMZ002)
• Vigabatrin (Vigabatrin)

Snippet

Sponsor: Amzell | Conditions: Spasms, Infantile | Phase 3 | Status: WITHDRAWN